INTRODUCTION

Colorectal cancer is the fourth leading cause of cancer-related death due to a poor prognosis. In this study, we investigated the effect of Gomisin G on colon cancer growth and examined the underlying mechanism of action. We found that Gomisin G significantly suppressed the viability and colony formation of LoVo cells. Gomisin G reduced the phosphorylation level of AKT implying that Gomisin G suppressed the PI3K-AKT signaling pathway. Gomisin G also induced apoptosis shown by Annexin V staining and an increased level of cleaved poly-ADP ribose polymerase (PARP) and Caspase-3 proteins. Furthermore, Gomisin G remarkably triggered the accumulation of cells at the sub-G1 phase which represents apoptotic cells. In addition, the level of cyclin D1 and phosphorylated retinoblastoma tumor suppressor protein (Rb) was also reduced by the treatment with Gomisin G thus curtailing cell cycle progression. These findings show the suppressive effect of Gomisin G by inhibiting proliferation and inducing apoptosis in LoVo cells. Taken together, these results suggest Gomisin G could be developed as a potential therapeutic compound against colon cancer.

Key Words: Gomisin G, Colon cancer, AKT, Apoptosis, PARP, Cell cycle

Gomisin G Suppresses the Growth of Colon Cancer Cells by Attenuation of AKT Phosphorylation and Arrest of Cell Cycle Progression

Sony Maharjan1,†, Byoung Kwon Park1,†, Su In Lee1, Yoongho Lim2, Keunwook Lee3, Younghee Lee4 and Hyung-Joo Kwon1,5,*

1Center for Medical Science Research, College of Medicine, Hallym University, Chuncheon 24252,
2Division of Bioscience and Biotechnology, BMIC, Konkuk University, Seoul 05029,
3Department of Biomedical Science, College of Natural Science, Hallym University, Chuncheon 24252,
4Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju 28644,
5Department of Microbiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea

Abstract

Colorectal cancer is one of the leading causes of cancer related death due to a poor prognosis. In this study, we investigated the effect of Gomisin G on colon cancer growth and examined the underlying mechanism of action. We found that Gomisin G signifi-

Received Mar 26, 2018 Revised May 1, 2018 Accepted May 17, 2018 Published Online Jun 14, 2018

*Corresponding Author
E-mail: hjookwon@hallym.ac.kr
Tel: +82-33-248-2635, Fax: +82-33-241-3640
†The first two authors contributed equally to this work.

Copyright © 2019 The Korean Society of Applied Pharmacology www.biomolther.org

This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licens-
es/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

210
have anti-HIV, anti-liver cancer and anti-inflammatory activities (Chen et al., 1997; Ryu et al., 2011; Xiaoyang et al., 2015). In a previous study, we found that Gomisin G has promise as a therapeutic agent against triple-negative breast cancer cells via an AKT-cyclin D1 dependent mechanism (Maharjan et al., 2018).

Apoptosis is an important cellular process characterized by regulated cell death. Collective evidence has shown that apoptotic cell death is a major target in the prevention and treatment of cancer (Ichim and Tait, 2016). The phosphatidylinositol 3-kinase (PI3K) /AKT signaling pathway is vital for intracellular signal transduction processes such as proliferation, apoptosis, survival, cell cycle progression and differentiation (Fresno Vara et al., 2004; Osaki et al., 2004). It has often been associated with the development and metastasis of various human cancers (Fresno Vara et al., 2004; Osaki et al., 2004). The expression of phospho-AKT and AKT has been found to be higher in colorectal cancer tissues than healthy tissues ones (Johnson et al., 2010).

The aim of the present study was to investigate the inhibitory effect of Gomisin G on growth, apoptosis, and cell cycle progression in a colon cancer cell line LoVo. We also examined the underlying mechanisms of action.

MATERIALS AND METHODS

Gomisins

Gomisin G, D, J, N and O were purchased from Biopurify Phytochemicals Ltd (Sichuan, China). The purity of the Gomisins were measured using an Agilent 1100 series high performance liquid chromatography (HPLC) system fitted with a RP-C18 column (Gemini, 5 μm, 4.6×250 mm; Phenomenex, Torrance, CA, USA) at room temperature as previously described (Maharjan et al., 2018). A UV/VIS detector (Agilent Technologies, Santa Clara, CA, USA) was used to measure the absorbance at 220 nm. The mobile phase was 65% aqueous acetonitrile, and the flow rate was 3.0 mL/min. Its chromatogram showed 98% purity; thus, it was used without further purification.

Cell culture

The human colon cancer cell line LoVo was purchased from the Korean Cell Line Bank (Seoul, Korea). The LoVo cells were originated from a fragment of a metastatic tumor nodule. The LoVo cells were maintained in RPMI1640 (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific), 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in an atmosphere of 5% CO2.

MTT assay

The MTT assay was performed as previously described (Li et al., 2017). LoVo cells were treated with Gomisin D, G, J, N and O each at a concentration of 0, 1, 5, and 10 μM, or with dimethyl sulfoxide (DMSO) as a control for 3 and 5 days. After the designated time, the cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO, USA) for 4 h at 37°C. The resultant formazan crystals were dissolved in DMSO, and the absorbance was detected at 570 nm using spectrophotometer (Molecular Devices, Orleans, CA, USA).

Colony formation assay

Five hundred cells per well were seeded in a 6 well-plate. After a 24 h incubation, the cells were treated with DMSO,
Gomisin G (10 µM) or Gomisin O (10 µM) and incubated for a further ten days at 37°C. The cells were then washed with PBS and stained with 0.4% crystal violet in methanol for 1 h. Images of the colonies were captured using ChemiDoc (Bio-Rad, Hercules, CA, USA).

Western blot analysis

Western blot was done as previously described (Shin et al., 2017). Briefly, the cell lysates were centrifuged at 14,000 rpm and 4°C. The proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked and probed with primary antibodies followed by incubation with HRP-conjugated secondary antibodies. The blots were detected using pAKT, AKT, pERK, ERK, pp38, and pRb antibodies. The blots were detected with pAKT, AKT, pERK, ERK, pp38, and pRb antibodies.

Annexin V and propidium iodide (PI) staining

To detect cell apoptosis, LoVo cells were treated with DMSO, Gomisin G (10 µM) or Gomisin O (10 µM) for 24 h and detached and washed with FACS buffer (1% FBS in PBS). The collected cells were resuspended in buffer containing annexin V (eBioscience, San Diego, CA, USA) for 15 min. at room temperature in the dark. The cells were washed and then incubated with PI (eBioscience) followed by analysis using a FACSCalibur (BD Biosciences, San Jose, CA, USA), and the data were analyzed with the Flowing software (Turku Centre for Biotechnology, Turun Yliopisto, Finland) (Sung et al., 2016).

Cell cycle analysis

LoVo cells treated with DMSO, Gomisin G (10 µM) or Gomisin O (10 µM) for 72 h were detached, collected and washed with FACS buffer (1% FBS in PBS). The cells were fixed with ice-cold 70% ethanol in PBS at 4°C overnight. After fixation, the cells were washed and resuspended in buffer containing RNase (Sigma-Aldrich) for 30 min. at 37°C. The cells were then incubated with PI and immediately analyzed with FACSCalibur (BD Biosciences).

RESULTS

Gomisin G inhibits the growth of LoVo cells

A previous study showed that Gomisin G blocked the proliferation of MDA-MB-231 triple negative breast cancer cells (Maharjan et al., 2018). To determine whether Gomisin G affects colon cancer cells, we investigated its effect on the viability of LoVo cells using the MTT assay. Treatment with Gomisin G significantly inhibited the growth of LoVo cells in a dose and time dependent manner (Fig. 1A). We also performed similar experiments using Gomisin D, J, N and O, which are natural compounds with a backbone structure similar to Gomisin G. While treatment with Gomisin N exhibited a mild suppressive effect, the other compounds failed to inhibit the viability of the LoVo cells. Among these compounds, Gomisin O was further used as a negative control in this study (Fig. 1A). To evaluate the long-term effect of Gomisin G, LoVo cells were grown in the presence of 10 µM Gomisin G for 10 days. As shown in Fig. 1B, there was a significant reduction in the numbers of colonies in the Gomisin G-treated wells. These data suggest that Gomisin G inhibits the growth of LoVo cells.

Gomisin G impairs the AKT signaling pathway in LoVo cells

Accumulated studies have shown the critical role of the

Fig. 2. Gomisin G mediated alteration of AKT phosphorylation in LoVo cells. LoVo cells were treated with 10 µM Gomisin G or Gomisin O for 24 h and lysed. Equal concentrations of proteins were separated by SDS-PAGE and transferred to membrane blots. The blots were detected with pAKT, AKT, pERK, ERK, pp38, and p38 antibodies. β-actin was used as a loading control.

Fig. 3. Apoptosis analysis of LoVo cells. (A) Cells were treated with 10 µM of Gomisin G or Gomisin O for 24 h. The Annexin V and PI detection kit was used for the detection of apoptosis and analyzed with FACSCalibur. (B) LoVo cells were treated with 10 µM of Gomisin G for 24 h and analyzed with immunoblotting. Blots were detected using PARP, cleaved Caspase-3, and β-actin antibodies.

https://doi.org/10.4062/biomolther.2018.054
Fig. 4. Effect of Gomisin G on cell cycle progression. (A) LoVo cells were treated with 10 μM Gomisin G or Gomisin O for 72 h, stained with PI, and analyzed with FACS Calibur. (B) LoVo cells were treated with 10 μM of Gomisin G or Gomisin O for 24 h, and the expression levels of cyclin D1, pRb and Rb were determined with immunoblotting. β-actin was used as a loading control.

**DISCUSSION**

Natural products from a vast range of natural sources such as plants, micro-organisms, marine organisms, and animals have excellent therapeutic significance since ancient times (Newman and Cragg, 2016). There have been numerous anticancer drugs derived from natural sources which have been identified and approved for use against various cancers (Newman and Cragg, 2016). The lignans in the fruit of Schisandra chinensis have been extensively used as oriental medicine. These natural compounds have been reported to possess a wide range of therapeutic activities such as hepatoprotective, antioxidant, anticancer, and chemoprotective (Opletal et al., 2004; Opletal et al., 2014). In particular, Gomisin G showed an anti-tumor effect by inducing cell cycle arrest and the inhibition of AKT-cyclin D1 signaling in MDA-MB-231 triple negative breast cancer cells (Maharjan et al., 2018). Given the high death rate of colon cancer patients, the relapse of cancer even after surgery, and the prevailing toxicity and inadequate response rate to current therapeutic regimens (Arnold et al., 2017), there has been immense pressure to identify promising natural anticancer agents that have low toxicity. Here, we show that Gomisin G has potential as a therapeutic agent against colon cancer.

The fundamental mechanism by which tumor cells oppose death is gaining resistance to apoptosis, and thus, it is a crucial point in the development of anticancer drugs (Fresco Vara et al., 2004; Danielsen et al., 2015). In this study, we found that Gomisin G significantly suppressed the viability of the colon cancer cell line LoVo. In addition, colony formation was sharply reduced in Gomisin G-treated cells, which further supports the growth-inhibitory action of Gomisin G (Maharjan et al., 2018). Moreover, the results of Annexin V and PI staining indicate that Gomisin G induced apoptosis in the LoVo cells.

There are two ways by which the apoptotic signaling exerts oncogenic effects: one is through the intrinsic (the mito-

\[ D1 \]

\[ \text{PI3K/AKT signaling pathway in the proliferation, development, and metastasis of many human cancers (Freso Vara et al., 2004; Osaki et al., 2004). To evaluate the role of the AKT signaling pathway in the Gomisin G-mediated inhibition of colon cancer cell growth, LoVo cells were treated with or without Gomisin G (10 μM), and western blot analysis was performed. Gomisin G treatment significantly reduced the phosphorylation level of AKT (Fig. 2). However, Gomisin G had no effect on the MAP kinase pathway shown by the unaltered phosphorylation levels of ERK and p38. In contrast, Gomisin O did not affect the phosphorylation level of AKT. These data indicate that Gomisin G might suppress the growth of LoVo cells by inhibiting the AKT signaling pathway.}

**Gomisin G induces apoptosis in LoVo cells**

To investigate whether apoptosis is involved in the growth inhibition of Gomisin G in LoVo cells, the cells were treated with or without Gomisin G (10 μM) for 24 h. FACS analysis was conducted to detect annexin V-positive cells. Fig. 3A shows that the apoptotic cell population increased by more than four fold in the Gomisin G-treated LoVo cells compared with the untreated, DMSO- or Gomisin O-treated cells. Caspases have a critical role in the implementation of programmed cell death (apoptosis) (Boatright and Salvesen, 2003; Parrish et al., 2013). An increased level of cleaved Caspase-3 was seen in Gomisin G-treated cells whereas no effect was seen in the Gomisin O-treated cells (Fig. 3B). Cleavage of PARP is also regarded as a hallmark of apoptosis (Soldani and Scovassi, 2002). Treatment with 10 μM Gomisin G for 24 h elicited PARP cleavage (Fig. 3B). These results taken together demonstrate that Gomisin G effectively induces apoptosis in LoVo cells.

**Effect of Gomisin G on the cell cycle progression of LoVo cells**

FACS analysis of LoVo cells treated with or without Gomisin G showed DNA patterns representing sub-G1, G1, S, and G2M phases of the cell cycle. Gomisin G-treated LoVo cells showed a significantly higher population at the sub-G1 (S-G1) phase compared with the untreated, DMSO- or Gomisin O-treated cells. The percentage of the S-G1 phase represents induction of apoptosis by Gomisin G. Treatment with Gomisin G led to a decrease in the population of cells in the G1 and G2M phase of the cell cycle. The G1 to G2/M ratio was higher in the Gomisin G-treated sample which implies moderate cell cycle arrest at the G0-G1 phase (Fig. 4A). Overexpression of cyclin D1 has been associated with the maintenance and development of cancer (Qie and Diehl, 2016). To illustrate the mechanism of cell death, we observed the expression of cyclin D1 and Rb, important cell cycle regulatory proteins (VanArsdale et al., 2015). Following the treatment of Gomisin G (10 μM), the levels of cyclin D1 and phosphorylated Rb were slightly decreased (Fig. 4B). Therefore, these results imply that cell cycle progression in the LoVo cells is impaired by the treatment with Gomisin G.
chondrial) pathway and the other through the extrinsic (death receptor) pathway (Ichim and Tait, 2016). Caspases are the fundamental proteins known to be involved in apoptotic cell death (Boatright and Salvesen, 2003; Parrish et al., 2013). In both pathways, Caspase-3 is the vital effector protein of apoptosis, which is activated by signals from initiator caspases like Caspase-8 and Caspase-9 (Boatright and Salvesen, 2003; Parrish et al., 2013). One of the regulatory cellular substrates of caspase is PARP, and its cleavage is regarded as a characteristic of apoptosis (Kauffman et al., 1993; Soldani and Scovassi, 2002; Chaitanya et al., 2010). In this study, we found an increased level of cleaved Caspase-3 in Gomisin G-treated cells. Furthermore, we also observed a prominent increase of cleaved PARP when the LoVo cells were treated with Gomisin G. These data suggest that Gomisin G induces apoptosis by regulating PARP and Caspase-3.

PI3K/AKT is one of the important intracellular signaling pathways regulating cell growth, proliferation, differentiation, metabolism, survival and apoptosis (Fresno Vara et al., 2004; Engelman, 2009; Danielsen et al., 2015). Several studies have reported frequent aberrant expression of PI3K/AKT signaling in cancer pathogenesis (Vivanco and Sawyers, 2002). Furthermore, PI3K/AKT signaling has a vital role in the development, maintenance, and metastasis of colorectal cancer (Engelman, 2009; Malinowsky et al., 2014; Danielsen et al., 2015). Therapeutic molecules inhibiting PI3K/AKT signaling have been recommended for use against colon cancer. (Engelman, 2009; Malinowsky et al., 2014; Danielsen et al., 2015). Previously, we found that Gomisin G diminished AKT phosphorylation in MDA-MB-231 breast cancer cells (Mahanj et al., 2018). Accordingly, the treatment of LoVo cells with Gomisin G also effectively inhibited the phosphorylation of AKT while the treatment with Gomisin G did not induce any changes in AKT phosphorylation. A very well-known protein AKT while the treatment with Gomisin O did not induce any changes in AKT phosphorylation. A very well-known protein AKT while the treatment with Gomisin O did not induce any changes in AKT phosphorylation. A very well-known protein AKT while the treatment with Gomisin O did not induce any changes in AKT phosphorylation. A very well-known protein AKT while the treatment with Gomisin O did not induce any changes in AKT phosphorylation. A very well-known protein AKT while the treatment with Gomisin O did not induce any changes in AKT phosphorylation.
cyclin D1. *Biomol. Ther. (Seoul)* **26**, 322-327.

Min, H. Y., Park, E. J., Hong, J. Y., Kang, Y. J., Kim, S. J., Chung, H. J., Woo, E. R., Hung, T. M., Yoon, U. J., Kim, Y. S., Kang, S. S., Bae, K. and Lee, S. K. (2008) Antiproliferative effects of dibenzocyclooctadiene lignans isolated from *Schisandra chinensis* in human cancer cells. *Bioorg. Med. Chem. Lett.* **18**, 523-526.

Moriarty, A., O’Sullivan, J., Kennedy, J., Mehigan, B. and McCormick, P. (2016) Current targeted therapies in the treatment of advanced colorectal cancer: a review. *Ther. Adv. Med. Oncol.* **8**, 276-293.

Navarro, M., Nicolas, A., Ferrandez, A. and Lanas, A. (2017) Colorectal cancer population screening programs worldwide in 2016: An update. *World J. Gastroenterol.* **23**, 3632-3642.

Newman, D. J. and Cragg, G. M. (2016) Natural products as sources of new drugs from 1981 to 2014. *J. Nat. Prod.* **79**, 629-661.

Oh, S. Y., Kim, Y. H., Bae, D. S., Um, B. H., Pan, C. H., Kim, C. Y., Lee, H. J. and Lee, J. K. (2010) Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated from the fruit of *Schisandra chinensis*. *Biosci. Biotechnol. Biochem.* **74**, 285-291.

Ogino, S., Noshio, K., Irahara, N., Kure, S., Shima, K., Baba, Y., Toyoda, S., Chen, L., Giovannucci, E. L., Meyerhardt, J. A. and Fuchs, C. S. (2009) A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. *Clin. Cancer Res.* **15**, 4431-4438.

Opletal, L., Sovova, H. and Bartlova, M. (2004) Dibenzo[a,c]cyclooctadiene lignans of the genus Schisandra: importance, isolation and determination. *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* **812**, 357-371.

Ormerod, M. G. (1998) The study of apoptotic cells by flow cytometry. *Leukemia* **12**, 1013-1025.

Osaki, M., Oshimura, M. and Ito, H. (2004) PI3K-Akt pathway: its functions and alterations in human cancer. *Apoptosis* **9**, 667-676.

Park, H. J., Lee, S. J., Song, Y., Jang, S. H., Ko, Y. G., Kang, S. N., Chung, B. Y., Kim, H. D., Kim, G. S. and Cho, J. H. (2014) *Schisandra chinensis* prevents alcohol-induced fatty liver disease in rats. *J. Med. Food* **17**, 103-110.

Parrish, A. B., Freel, C. D. and Kornbluth, S. (2013) Cellular mechanisms controlling caspase activation and function. *Cold Spring Harb. Perspect. Biol.* **5**, a008672.

Qie, S. and Diehl, J. A. (2016) Cyclin D1, cancer progression, and opportunities in cancer treatment. *J. Mol. Med.* **94**, 1313-1326.

Ryu, E. Y., Park, S. Y., Kim, S. G., Park, D. J., Kang, J. S., Kim, Y. H., Seetharaman, R., Choi, Y. W. and Lee, S. J. (2011) Anti-inflammatory effect of heme oxygenase-1 toward *Porphyromonas gingivalis* lipopolysaccharide in macrophages exposed to gomisins A, G and J. *J. Med. Food* **14**, 1519-1526.

Soldani, C. and Scovassi, A. I. (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. *Aptoptosis* **7**, 321-328.

Shin, D. W., Kwon, Y. J., Ye, D. J., Baek, H. S., Lee, J. E. and Chun, Y. J. (2017) Auranofin suppresses plasminogen activator inhibitor-2 expression through annexin A5 induction in human prostate cancer cells. *Biomol. Ther. (Seoul)* **25**, 177-185.

Sung, N. Y., Kim, S. C., Kim, Y. H., Kim, G., Lee, Y., Sung, G. H., Kim, J. H., Yang, W. S., Kim, M. S., Baek, K. S. and Cho, J. Y. (2016) Anti-proliferative and pro-apoptotic activities of 4-methyl-2,6-bis(1-phenylethyl)phenol in cancer cells. *Biomol. Ther. (Seoul)* **24**, 402-409.

VanArsdale, T., Boshoff, C., Arndt, K. T. and Abraham, R. T. (2015) Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. *Clin. Cancer Res.* **21**, 2905-2910.

Vivanco, I. and Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. *Nat. Rev. Cancer* **2**, 489-501.

Xiaoyang, L., Chenming, N., Chengqing, L. and Tao, L. (2015) Drug-drug interaction prediction between ketoconazole and anti-liver cancer drug Gomisin G. *Afr. Health Sci.* **15**, 590-593.